GLP-1-Based Therapies in Type 2 Diabetes and Obesity: Current Evidence, Cardiorenal Benefits, Safety and Future Directions

Authors

  • Ozodbekova Umidakhon Andijan State Medical Institute image/svg+xml Author

Keywords:

type 2 diabetes mellitus, obesity, GLP-1 receptor agonists, incretin-based therapy, semaglutide, tirzepatide, cardiovascular outcomes, chronic kidney disease

Abstract

Type 2 diabetes mellitus (T2DM) and obesity are closely interrelated chronic metabolic diseases that substantially increase cardiovascular and kidney risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer incretin-based agents have expanded the therapeutic goals of endocrinology beyond glucose lowering and weight reduction toward cardiovascular risk modification and, for selected agents and populations, kidney protection. The aim of this narrative review was to synthesise the physiological rationale, glycaemic and weight efficacy, cardiovascular and kidney outcome evidence and safety of GLP-1-based therapies, and to formulate practical principles for their use in individualised care. Major randomised outcome trials, systematic reviews, consensus reports and professional guidance published predominantly between 2016 and 2025 were examined. In people with T2DM and high cardiovascular risk, liraglutide, subcutaneous semaglutide and dulaglutide reduced major adverse cardiovascular events (MACE) by 12–26 % relative to placebo. In people with overweight or obesity and established cardiovascular disease without diabetes, semaglutide 2.4 mg reduced MACE by 20 %, and in T2DM with chronic kidney disease (CKD) semaglutide reduced a composite of major kidney outcomes by 24 %. Weekly semaglutide 2.4 mg and tirzepatide produced mean weight reductions of approximately 15 % and up to 21 %, respectively, in obesity trials. Gastrointestinal adverse effects are the most common limitation and are largely dose-related. GLP-1-based therapies should be selected through shared decision-making on the basis of agent-specific evidence and integrated with SGLT2 inhibitors, lifestyle intervention and comprehensive risk-factor management rather than used as substitutes for them

References

1. American Diabetes Association Professional Practice Committee. (2025a). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2025. Diabetes Care, 48(Suppl. 1). https://diabetesjournals.org/care/issue/48/Supplement_1

2. American Diabetes Association Professional Practice Committee. (2025b). 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes—2025. Diabetes Care, 48(Suppl. 1). https://diabetesjournals.org/care/issue/48/Supplement_1

3. American Diabetes Association Professional Practice Committee. (2025c). 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2025. Diabetes Care, 48(Suppl. 1). https://diabetesjournals.org/care/issue/48/Supplement_1

4. Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., et al. (2022). Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753–2786. https://doi.org/10.2337/dci22-0034

5. Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3

6. Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446. https://doi.org/10.1056/NEJMoa2024816

7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

8. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1–S127. https://doi.org/10.1016/j.kint.2022.06.008

9. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563

10. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141

11. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827

12. Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347

13. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Downloads

Published

13.11.2026

Issue

Section

Articles

How to Cite

Ozodbekova, U. (2026). GLP-1-Based Therapies in Type 2 Diabetes and Obesity: Current Evidence, Cardiorenal Benefits, Safety and Future Directions. Bulletin of Contemporary Researches, 2(4), 118-123. https://bulconre.com/index.php/mult/article/view/54